Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
AUSTIN, Texas , May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Compan
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
08:00am, Monday, 12'th May 2025
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel the
Keros Reinforces Commitment to Maximizing Stockholder Value
05:31pm, Thursday, 08'th May 2025
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 202
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders
02:10pm, Thursday, 08'th May 2025
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth AUSTIN, Texas , May 8, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates
08:10pm, Tuesday, 06'th May 2025
Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $3.62 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $1.21 per share a year
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
04:01pm, Tuesday, 06'th May 2025
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and comm
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
01:00pm, Friday, 11'th Apr 2025
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
01:51pm, Thursday, 10'th Apr 2025
Keros Therapeutics, Inc.‘s KROS board of directors initiated a formal review process on Thursday to evaluate strategic alternatives, including a sale.
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
12:12pm, Thursday, 10'th Apr 2025
U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 4% on Thursday.
Keros Therapeutics adopts 'poison pill' plan
06:10am, Thursday, 10'th Apr 2025
Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.
Keros Therapeutics Announces Review of Strategic Alternatives
06:00am, Thursday, 10'th Apr 2025
LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and co
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
06:00am, Monday, 31'st Mar 2025
LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel t
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet
10:55am, Friday, 21'st Mar 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable,
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade
10:56am, Wednesday, 05'th Mar 2025
The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
05:00pm, Friday, 28'th Feb 2025
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
